March 15, 2024
Loading...
You are here:  Home  >  'Amgen'  -  Page 7
Latest

Amgen to team with Eli Lilly on COVID treatment

By   /  Friday, September 18th, 2020  /  Banking & Finance, East Ventura County, Health Care & Life Science, Latest news, Technology, Tri-County Economy, Tri-County Public Companies  /  Comments Off on Amgen to team with Eli Lilly on COVID treatment

Thousand Oaks biotech giant Amgen announced another strategy to help address the coronavirus pandemic, entering into a manufacturing agreement with Eli Lilly to produce COVID-19 antibodies.  Eli Lilly, based in Indianapolis, has been pursuing several antibody treatments for the virus, the two companies said in a Sept. 17 news release. With access to Amgen’s manufacturing Read More →

Latest

Sonos, Amgen, Teledyne lead the region in patents

By   /  Saturday, September 5th, 2020  /  middle  /  Comments Off on Sonos, Amgen, Teledyne lead the region in patents

Corporate research and development departments in the Tri-Counties churned out hundreds of new inventions in 2020, driving strong patent activity that has been undeterred by the coronavirus pandemic. A Business Times analysis of 975 patents granted to area inventors in the last 12 months showed imaging and semiconductor technologies remain some of the top avenues Read More →

Latest

Apple, Tesla thrive with stock splits, but are they a fad?

By   /  Saturday, September 5th, 2020  /  Banking Industry, Latest news  /  Comments Off on Apple, Tesla thrive with stock splits, but are they a fad?

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Latest

Making an ImmPACT: New firm raises $18M to pursue T-cell therapies

By   /  Friday, August 28th, 2020  /  Health Care & Life Science, Latest news  /  Comments Off on Making an ImmPACT: New firm raises $18M to pursue T-cell therapies

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Latest

Amgen to join exclusive Dow Jones club

By   /  Monday, August 24th, 2020  /  Banking & Finance, East Ventura County, Health Care & Life Science, Latest news, Tri-County Economy, Tri-County Public Companies  /  Comments Off on Amgen to join exclusive Dow Jones club

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Latest

Amgen teams up with competitors in COVID treatment trial

By   /  Monday, August 3rd, 2020  /  East Ventura County, Health Care & Life Science, Latest news, Tri-County Public Companies  /  Comments Off on Amgen teams up with competitors in COVID treatment trial

Amgen has joined two of its competitors in launching a trial for drugs to treat patients with COVID-19. Together with Chicago-based AbbVie and Japanese drugmaker Takeda Pharmaceutical, the Thousand Oaks biotech giant said Aug. 3 it had enrolled the first patients into a clinical trial for the anti-inflammatory drugs Otezla, cenicriviroc and Firazyr. Otezla is Read More →

Latest

Amgen meets analyst estimates, but shares drop on Q2 earnings decline

By   /  Tuesday, July 28th, 2020  /  Banking & Finance, Earnings, East Ventura County, Health Care & Life Science, Latest news, Tri-County Economy, Tri-County Public Companies  /  Comments Off on Amgen meets analyst estimates, but shares drop on Q2 earnings decline

Amgen’s revenues climbed 6 percent in the second quarter, to $6.2 billion, despite the COVID-19 pandemic limiting hospital and physician operations and putting a hitch in diagnosis and treatment for many patients. Amgen’s earnings, announced July 28, met average analyst estimates. However, a 17 percent overall decline in net income for the Thousand Oaks biotech Read More →